---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134558"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T06:03:26.551339+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences appoints Mark K. Oki as CFO effective December 5, 2024

## Summary
- Mark Oki previously CFO of Aytu Biopharma, Vivus LLC, Alexza Pharmaceuticals.
- Base salary $450,000/year; annual discretionary bonus up to 40% of base.
- Awarded option for 72,000 shares (1/3 vest year 1, then monthly) and 168,000 performance-based RSUs.
- Severance: 12 months salary (24 months on change in control) plus healthcare and accelerated equity vesting.

## SEC filing metadata
- accession: 0000950170-24-134558
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017024134558/0000950170-24-134558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017024134558/achv-20241205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134558
- JSON: https://secwatch.observer/filing/0000950170-24-134558.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.